May 19, 2020
Michael Rome, PhD Promoted to Managing Director
By Jim Tananbaum
Today we are pleased to announce the promotion of Dr. Michael Rome to managing director of Foresite Capital.
I founded this firm in 2011 to back visionary entrepreneurs in healthcare, regardless of company stage. I took my combined experience as an entrepreneur and an investor, and built the firm from the ground up to capitalize on opportunities that I believed would address the greatest unmet medical needs while also emphasizing the use of data science tools in healthcare. I’m proud of what we’ve accomplished. In the present environment healthcare and science are in the spotlight more than ever before.
Over the years, our team has grown to include some of the pre-eminent thinkers in the life sciences, healthcare and data science. Michael is one of those people. We recruited him to join the firm in 2016, recognizing his talent and potential. He brings a wealth of experience that has proven invaluable in evaluating both private and public investment opportunities. He led our public investment in Blueprint Medicines, and played significant roles in our private investments in Turning Point Therapeutics, and Nurix Therapeutics. We worked closely together on the founding of https://www.kinnate.com/. He is incredibly personable and is highly regarded by the entrepreneurs he has worked with over the years. He has a great ability to bring together all the elements for a successful investment.
One of the most rewarding parts of running a firm is mentoring and growing talented individuals. I’m proud of the group of managing directors leading our firm, and glad to have Michael join our team.
Michael works out of our New York office alongside our East Coast managing directors Matt Buten, Dorothy Margolskee and Brett Zbar.
We look forward to many more years of collaboration with Michael. Congratulations, Michael, and welcome to the managing director team!